CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options

About this update from Cvs Health Corporation

Expanded GLP-1 options for members create a path to sustainable coverage of these important medications WOONSOCKET, RI / ACCESS Newswire / June 10, 2026 / Originally published on CVS Health Company Newsroom CVS Health (NYSE:CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members- including the reintroduction of Zepbound® (tirzepatide) as a covered medication. These changes build on Caremark's industry leading efforts as a pharmacy benefits manager to explore all potential avenues that help patients get FDA-approved weight management medications at an affordable cost. Plan sponsors that adopt CVS Caremark template formularies retain discretion to customize coverage for their members. What changes is CVS Caremark making to its weight management drug coverage? CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members. Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo™(orforglipron), a new oral GLP-1 therapy, where approved for coverage by plans. Over the past year, we've been actively driving change in the GLP-1 weight management space to help lower costs. Our approach has made a real difference, enabling us to now expand options while continuing to make progress on affordability. We expect these changes to help drive increased savings in the weight management category - after a history of delivering double digit savings for our template formulary customers year over year - while expanding choice for our members. Why is CVS Caremark adding Zepbound to their formulary? Simply put, we achieved what our customers asked us for: deliver affordability and optionality in this important class. "We're creating access and options that would not have existed without our leadership in the market," said Ed DeVaney, President, CVS Caremark. "We acted boldly through active engagement and negotiation with our drug manufacturer partners to tackle affordability and access for our customers and their members." What is CVS Caremark doing to bring down the cost of GLP-1s? Over the past two years, high prices have put these therapies out of reach for t...

View stock analysis, news, and events for Cvs Health Corporation